COVID-19 vaccines are being subject to heightened safety scrutiny because of the speed of their development and regulatory clearance under the emergency use authorization pathway and because of the unusual amount of public attention on the rollout, given the vaccines potential to dampen a global pandemic. A third unique element is the evolving nature of the virus the vaccines are targeting.
Pandemic Perspectives
One year on from the World Health Organization declaring COVID-19 a global pandemic on 11 March 2020, editors across Informa Pharma Intelligence publications are taking a closer look at its impact and possible lasting implications for the biopharma and medtech industry.
To address the unusual challenge, the US has upped its safety efforts, creating two new pharmacovigilance systems for COVID-19 vaccines...